查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947945

補體抑制劑市場依產品類型、適應症、給藥途徑、通路和最終用戶分類，全球預測（2026-2032年）

Complement Inhibitors Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

補體抑制劑市場預計到 2025 年將達到 139.4 億美元，到 2026 年將成長到 152.2 億美元，到 2032 年將達到 269.1 億美元，年複合成長率為 9.84%。

關鍵市場統計數據
基準年 2025 139.4億美元
預計年份：2026年 152.2億美元
預測年份 2032 269.1億美元
複合年成長率 (%) 9.84%

補體抑制劑策略架構：重點在於相關人員的科學進展、臨床差異化和跨職能優先事項

補體抑制劑處於免疫學、神經病學、腎臟病學和罕見疾病治療的交叉領域，代表著一個動態發展的治療領域，其發展受到精準生物學和標靶遞送技術創新的推動。近年來，高品質臨床證據的累積、監管核准的不斷擴大以及多種給藥方式的開發，共同提升了生物製藥開發商、支付方和專科醫療機構的策略關注度。隨著各公司不斷完善作用機制，並透過便捷的給藥方式、安全性以及給藥途徑實現差異化，競爭格局日益取決於臨床差異化和卓越的運營，而非單一產品的優勢。

補體抑制療法中不斷發展的治療模式、遞送創新和臨床整合將如何重塑研發和商業化策略

補體抑制劑領域正經歷變革性的轉變，這主要得益於給藥方式多樣化、遞送技術創新以及補體生物學臨床應用的拓展。單株抗體不斷改進，以延長半衰期並降低免疫抗原性；同時，胜肽、 RNA干擾療法和小分子藥物也不斷豐富全身性和標靶性補體調節的工具庫。這種給藥方式的轉變正在改變藥物研發模式，使得更靈活的給藥方案和替代給藥途徑成為可能，這對於慢性疾病的治療和提高患者依從性尤其重要。

評估2025年美國關稅趨勢對補體抑制劑供應韌性、籌資策略和商業化路徑的影響

貿易政策趨勢和關稅措施將對整個醫藥價值鏈產生多層次的影響，而2025年美國關稅的累積效應很可能波及補體抑制劑的採購、生產和分銷管道。由於生物製藥和小分子藥物的許多原料、關鍵試劑和特殊成分都依賴全球採購，進口成本上升和物流中斷可能會促使製造商重新評估其供應商所在地和庫存策略。這可能導致近岸外包和雙重採購策略的加速推進，旨在降低貿易摩擦的風險，同時維持供應的連續性。

詳細的細分分析揭示了產品形態、治療適應症、給藥途徑、分銷管道和終端用戶環境如何相互作用，從而影響策略制定。

深入了解產品類型、臨床適應症、給藥途徑、分銷管道和終端用戶環境之間的相互作用，對於制定研發和商業策略至關重要。依產品類型分類，市場涵蓋單株抗體、胜肽、 RNA干擾療法和小分子藥物。單株抗體包括傳統藥物和長效藥物，例如已上市的補體抑制劑抗體和新一代工程變體。肽類藥物包含具有不同藥物動力學特徵的標靶抑制劑。 RNA干擾療法著重於肝臟和全身通路調控。小分子藥物提供口服或輔助治療方案，其生產和定價機制各不相同。對於單株抗體而言，速效和長效藥物之間的差異會影響其臨床應用以及靜脈給藥的可能性。

區域趨勢與策略意義：了解美洲、歐洲、中東和非洲以及亞太地區的環境將如何影響臨床應用和進入途徑

區域趨勢反映了不同地區法規環境、醫療服務模式和相關人員期望的差異，這些差異對補體抑制劑的研發、上市和應用產生了重大影響。在美洲，重點在於創新成果的商業化和與支付方的談判，臨床網路和專科醫療中心促進了藥物准入途徑的建立和真實世界證據的生成。同時，歐洲、中東和非洲的監管和報銷環境各不相同，各國特定的衛生技術評估流程和區域採購慣例實踐要求制定量身定做的准入策略並儘早與支付方接洽。在亞太地區，快速發展的醫療基礎設施、新興的專科醫療中心以及對本地生產和臨床研究能力的不斷成長的投資共同塑造了市場動態。

競爭格局評估揭示了現有企業、創新新參與企業、製造合作夥伴和支付方如何塑造差異化和市場動態。

補體抑制劑領域的競爭格局由兩類企業組成：一類是擁有臨床驗證資產的成熟開發商，另一類是推出差異化療法和給藥途徑的新創企業。已證實具有臨床療效的現有計畫在安全性和持久性方面樹立了高標準，而創新者則專注於透過改善給藥途徑、減輕治療負擔和拓展適應症來滿足未被滿足的醫療需求。夥伴關係與授權協議仍然是加速分子開發和商業性擴張的關鍵，策略聯盟的建立旨在整合臨床專長、生產能力和市場進入資源。

為確保永續優勢，提出整合科學差異化、供應鏈韌性和以支付方為中心的實證項目的實用策略建議。

產業領導者應採取整合策略，加速臨床差異化，同時增強營運韌性並加強與支付方的合作。首先，優先對治療方法多樣性和靈活的給藥方式進行策略性投資，以減輕治療負擔並擴大服務點。其次，推廣以生物標記主導的項目和務實的試驗設計，以加快獲得可操作證據的速度，並支持有針對性的報銷談判。第三，在需求出現之前，投資供應鏈冗餘、本地製造夥伴關係以及庫存策略，以降低受貿易政策和物流中斷的影響。

一種透明且可重複的混合方法調查方法，結合了專家訪談、系統文獻綜述和三角驗證技術，以得出可操作的研究結果。

本報告整合了多種研究方法，以確保其穩健性、可靠性和實用性。主要研究包括對臨床意見領袖、商業高管、生產專家和支付方進行深入訪談，以收集有關臨床實踐、准入趨勢和營運限制的最新見解。次要研究包括對同行評審文獻、監管文件、臨床指南和公司披露資訊進行系統性回顧，以闡明主要研究結果並檢驗技術假設。資料三角測量法整合了定量和定性訊息，以調和相互衝突的觀點並突出共識趨勢。

將科學創新、運作韌性和實證准入策略相結合的整體性綜合方法是補體抑制劑療法成功的先決條件。

總之，補體抑制劑正從一個利基治療領域向一個多方面治療領域轉型，其治療方式多樣，適應症不斷擴大，給藥模式也在不斷演變，這些變化共同帶來了巨大的機會和運作上的複雜性。抗體工程、胜肽設計、 RNA干擾和小分子化學領域的科學進步正在創造差異化的臨床特徵，而給藥和分銷方式的改變則有助於擴大臨床覆蓋範圍並實現以患者為中心的模式。同時，供應鏈的脆弱性、貿易政策的不確定性以及支付方的嚴格審查都要求我們積極主動地進行風險管理，並進行基於循證醫學的價值溝通。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章補體抑制劑市場（依產品類型分類）

  • 單株抗體
    • Eculizumab
    • Ravulizumab
  • 胜肽
  • RNAi療法

第9章補體抑制劑市場依適應症分類

  • 非典型溶血性尿毒症候群
    • 成年患者
    • 兒童患者
  • 重症肌無力
    • 系統
    • 眼球型
  • 視神經脊髓炎頻譜障礙
    • AQP4 陰性
    • AQP4陽性
  • 陣發性睡眠性血尿症
    • 成年患者
    • 兒童患者

第10章補體抑制劑市場依給藥途徑分類

  • 靜脈注射
  • 口服
  • 皮下注射

第11章補體抑制劑市場依分銷管道分類

  • 線上
  • 離線

第12章補體抑制劑市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 專科診所
    • 腎臟病診所
    • 神經病學中心

第13章補體抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章補體抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國補體抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國補體抑制劑市場

第17章：中國補體抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Eli Lilly and Company
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • UCB SA
Product Code: MRR-4F7A6D4FB69B

The Complement Inhibitors Market was valued at USD 13.94 billion in 2025 and is projected to grow to USD 15.22 billion in 2026, with a CAGR of 9.84%, reaching USD 26.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.94 billion
Estimated Year [2026] USD 15.22 billion
Forecast Year [2032] USD 26.91 billion
CAGR (%) 9.84%

A strategic framing of complement inhibitors highlighting scientific advances, clinical differentiation, and cross-functional priorities for stakeholders

Complement inhibitors are at the intersection of immunology, neurology, nephrology, and rare disease therapeutics, representing a dynamically evolving class shaped by precision biology and targeted delivery innovations. Recent years have seen the convergence of high-quality clinical evidence, expanded regulatory approvals, and diversified modality development that collectively have elevated strategic interest from biopharma developers, payers, and specialist providers. As companies refine mechanisms of action and differentiate through dosing convenience, safety profiles, and administration routes, the competitive landscape is increasingly defined by clinical differentiation and operational excellence rather than single-asset dominance.

Moreover, ongoing advances in biomarker science and patient stratification are enabling more precise indication targeting, which, in turn, is reshaping trial design and commercial access approaches. Concurrently, payers and health systems are emphasizing value-based care and outcomes measurement, prompting developers to incorporate health economics into clinical programs earlier. Given these convergent forces, stakeholders must navigate complex regulatory pathways, supply chain imperatives, and payer expectations while capitalizing on opportunities to expand into adjacent indications and alternative care settings. Ultimately, the therapeutic promise of complement inhibition depends not only on clinical efficacy but also on strategic alignment across development, commercialization, and delivery systems.

How evolving modalities, delivery innovations, and clinical integration are reshaping development and commercialization strategies across complement inhibition therapies

The landscape for complement inhibitors is undergoing transformative shifts driven by advances in modality diversity, delivery innovation, and expanded clinical application of complement biology. Monoclonal antibodies continue to be refined for improved half-life and reduced immunogenicity, while peptides, RNA interference therapeutics, and small molecules are broadening the toolkit for both systemic and targeted complement modulation. These modality shifts are changing development paradigms, enabling more flexible dosing regimens and alternative routes of administration, which are especially important for chronic indications and for improving patient adherence.

At the same time, clinical practice is adapting as neurologists, nephrologists, and hematologists incorporate new therapeutic options that change patient pathways and care settings. Real-world evidence initiatives and post-authorization data collection are informing optimized positioning and reimbursement conversations. In addition, the industry is witnessing a maturation of commercial strategies where lifecycle planning, combination approaches, and label expansion are central to sustaining therapeutic relevance. Taken together, these shifts create a landscape where scientific progress and pragmatic commercialization strategies converge, compelling organizations to re-evaluate partnerships, manufacturing footprints, and evidence-generation plans to sustain competitiveness.

Assessing how 2025 United States tariff developments can influence supply resilience, sourcing strategies, and commercialization pathways for complement inhibitors

Trade policy developments and tariff actions can create multilayered impacts across pharmaceutical value chains, and the cumulative effect of United States tariff measures in 2025 is likely to reverberate through sourcing, manufacturing, and distribution channels for complement inhibitors. Because many raw materials, critical reagents, and specialized components for biologics and small molecules are globally sourced, increased import costs or logistical disruptions can prompt manufacturers to reassess supplier footprints and inventory strategies. In turn, this can accelerate nearshoring or dual-sourcing initiatives aimed at reducing exposure to trade frictions while preserving continuity of supply.

Furthermore, tariff-induced cost pressures often lead to shifts in procurement priorities and contract negotiations, prompting contract manufacturers and suppliers to renegotiate terms or pass costs through to downstream stakeholders. For developers of next-generation modalities such as RNA interference therapeutics and novel peptides, where supply chains can be highly specialized, even modest trade barriers can increase complexity in batch release timelines and regulatory filings. As a consequence, organizations may prioritize supply-chain resilience, increase investment in domestic manufacturing capacity, or revise clinical supply strategies to protect trial integrity.

Regulatory agencies and payers may also respond to tariff-driven cost dynamics by scrutinizing pricing and reimbursement frameworks more closely, which could affect market access and formulary positioning. Therefore, companies should view tariff impacts as a catalyst to enhance operational agility, strengthen supplier relationships, and integrate trade-policy scenarios into risk-management frameworks that inform both short-term tactical moves and long-term strategic planning.

Detailed segmentation insights revealing how product modalities, therapeutic indications, administration routes, distribution channels, and end-user settings converge to shape strategy

A granular understanding of how product types, clinical indications, routes of administration, distribution channels, and end-user settings interact is essential for shaping development and commercial strategies. For product type, the market spans monoclonal antibodies, peptides, RNA interference therapeutics, and small molecules, where monoclonal antibodies include legacy and long-acting agents such as established complement-blocking antibodies and next-generation engineered variants, peptides encompass targeted inhibitors with distinct pharmacokinetic profiles, RNAi therapeutics focus on hepatic and systemic pathway modulation, and small molecules offer oral or adjunctive options with different manufacturing and pricing dynamics. Within monoclonal antibodies, differentiation between rapidly acting and extended-interval agents influences clinic utilization and infusion capacity.

Across indications, therapies address a spectrum that includes atypical hemolytic uremic syndrome, myasthenia gravis, neuromyelitis optica spectrum disorder, and paroxysmal nocturnal hemoglobinuria, each with unique diagnostic complexity and patient management models. Subpopulations such as adult versus pediatric patients, generalized versus ocular manifestations, and seropositive versus seronegative cohorts necessitate tailored clinical evidence and access strategies. Route of administration is another axis of differentiation: intravenous delivery remains central to hospital- and clinic-based infusion models, oral formulations enable home administration and improved adherence, and subcutaneous options support clinic-based or self-administration paradigms that reduce healthcare resource utilization. Distribution channels further shape commercialization tactics, with hospital pharmacies supporting inpatient and outpatient infusion, online pharmacies enabling direct-to-patient logistics, and retail pharmacies serving chain and independent dispensing networks. Finally, end users span home care, hospitals, and specialty clinics, where home care may involve caregiver or self-administration, hospitals deliver complex inpatient care, and specialty clinics such as nephrology and neurology centers manage long-term treatment programs. Integrating these segmentation dimensions reveals how clinical, operational, and commercial choices must be coordinated to support patient access and product differentiation.

Regional dynamics and strategic implications illustrating how Americas, Europe Middle East & Africa, and Asia-Pacific environments influence clinical adoption and access pathways

Regional dynamics reflect distinct regulatory environments, healthcare delivery models, and stakeholder expectations that materially influence how complement inhibitors are developed, launched, and adopted. In the Americas, there is a strong emphasis on innovation commercialization and payer negotiation, with clinical networks and specialist centers facilitating access pathways and real-world evidence generation. Conversely, Europe, Middle East & Africa exhibits heterogeneous regulatory and reimbursement landscapes where country-specific health technology assessment processes and regional procurement practices demand tailored access strategies and early payer engagement. In Asia-Pacific, market dynamics are shaped by a mix of rapidly developing healthcare infrastructure, emerging specialist centers, and increasing investment in local manufacturing and clinical research capacity.

Moreover, cross-region differences in clinical practice patterns and diagnostic infrastructure affect patient identification and pathway design, while variations in reimbursement philosophies influence pricing and contracting approaches. Because these regional factors evolve in response to policy shifts, demographic trends, and local innovation ecosystems, organizations must align regulatory strategies, evidence generation plans, and commercial operations with regional priorities. By doing so, developers and commercial teams can optimize launches, design phased entry strategies, and allocate resources to maximize clinical impact and patient access across diverse geographic markets.

Competitive landscape assessment highlighting how incumbents, innovative entrants, manufacturing partners, and payers shape differentiation and market dynamics

Competitive dynamics in complement inhibition are defined by a mix of established developers with clinically validated assets and emerging players introducing differentiated modalities and delivery approaches. Incumbent programs with proven clinical outcomes set high bars for safety and durability, while innovators focus on addressing unmet needs through improved administration routes, reduced treatment burden, and expanded indication footprints. Partnerships and licensing deals continue to be central to accelerating molecule advancement and scaling commercial operations, with strategic alliances often formed to combine clinical expertise, manufacturing capacity, and market access capabilities.

Additionally, contract manufacturing organizations and specialized suppliers play critical roles in enabling commercial scale-up, and their capabilities often determine the feasibility and timing of alternative dosing strategies or new presentations. Meanwhile, payer and provider stakeholders increasingly demand robust comparative effectiveness data and long-term safety evidence, shaping the competitive playbook for second-generation agents. Collectively, these forces create a competitive environment where differentiation is driven by clinical value, operational readiness, and the ability to demonstrate measurable patient and system benefits over time.

Actionable strategic recommendations for leaders to align scientific differentiation, supply resilience, and payer-focused evidence programs for sustained advantage

Industry leaders should adopt an integrated playbook that accelerates clinical differentiation while strengthening operational resilience and payer engagement. First, prioritize strategic investments in diversified modalities and flexible delivery formats that reduce treatment burden and expand care settings. Second, advance biomarker-driven programs and pragmatic trial designs that shorten time to actionable evidence and support targeted reimbursement discussions. Third, invest ahead of demand in supply-chain redundancy, local manufacturing partnerships, and inventory strategies that mitigate exposure to trade policy and logistical disruptions.

In parallel, commercial teams must develop tailored access strategies aligned with regional payer expectations and clinician workflows, incorporating real-world evidence capture and outcomes-based contracting where appropriate. Collaboration is also essential: pursue targeted alliances to fill capability gaps, accelerate launches, or share development risk. Finally, embed health economics and outcomes research into clinical programs from the outset to facilitate formulary negotiations and to articulate value propositions convincingly. By executing a cohesive approach that blends scientific innovation with operational and commercial rigor, organizations can create sustainable advantages and improve patient access across therapeutic and geographic domains.

Transparent and reproducible mixed-methods research methodology combining expert interviews, systematic literature review, and triangulation for actionable intelligence

This report synthesizes multiple research approaches to ensure robustness, credibility, and practical relevance. Primary research consisted of in-depth interviews with clinical thought leaders, commercial executives, manufacturing experts, and payers, which provided contemporaneous perspectives on clinical practice, access dynamics, and operational constraints. Secondary research involved systematic review of peer-reviewed literature, regulatory documents, clinical guidelines, and company disclosures to contextualize primary findings and validate technical assumptions. Data triangulation integrated quantitative and qualitative inputs to reconcile divergent viewpoints and to highlight consensus trends.

Analytical methods included thematic coding of interview transcripts, comparative policy analysis across regulatory jurisdictions, and scenario planning to surface potential impacts of supply-chain and trade-policy developments. The methodology emphasized transparency and reproducibility, with source attribution for key claims and clearly documented inclusion criteria for secondary sources. Limitations were addressed through sensitivity checks and by incorporating multi-stakeholder perspectives to reduce bias. Taken together, this mixed-methods approach yields actionable intelligence that supports both strategic decision-making and operational execution.

Concluding synthesis that connects scientific innovation, operational resilience, and evidence-based access strategies as imperatives for success in complement inhibition

In summary, complement inhibitors are transitioning from a niche therapeutic category into a diversified class with multiple modalities, expanded indications, and evolving delivery paradigms that together present significant opportunities and operational complexities. Scientific advances in antibody engineering, peptide design, RNA interference, and small-molecule chemistry are creating differentiated clinical profiles, while shifts in administration and distribution enable broader care settings and patient-centric models. At the same time, supply-chain fragility, trade-policy uncertainty, and payer scrutiny demand proactive risk management and evidence-based value communication.

Consequently, organizations that align scientific innovation with robust manufacturing strategies, targeted evidence generation, and regionally adapted commercialization plans will be best positioned to translate clinical promise into sustainable clinical uptake. Strategic partnerships, early payer engagement, and investments in real-world data infrastructure will further enhance competitive positioning. Ultimately, success in this evolving ecosystem requires an integrated approach that balances short-term operational resilience with long-term investment in clinical differentiation and patient-centric access solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Complement Inhibitors Market, by Product Type

  • 8.1. Monoclonal Antibody
    • 8.1.1. Eculizumab
    • 8.1.2. Ravulizumab
  • 8.2. Peptide
  • 8.3. Rnai Therapeutic

9. Complement Inhibitors Market, by Indication

  • 9.1. Atypical Hemolytic Uremic Syndrome
    • 9.1.1. Adult Patients
    • 9.1.2. Pediatric Patients
  • 9.2. Myasthenia Gravis
    • 9.2.1. Generalized
    • 9.2.2. Ocular
  • 9.3. Neuromyelitis Optica Spectrum Disorder
    • 9.3.1. Aqp4 Negative
    • 9.3.2. Aqp4 Positive
  • 9.4. Paroxysmal Nocturnal Hemoglobinuria
    • 9.4.1. Adult Patients
    • 9.4.2. Pediatric Patients

10. Complement Inhibitors Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Complement Inhibitors Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Complement Inhibitors Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics
    • 12.3.1. Nephrology Clinics
    • 12.3.2. Neurology Centers

13. Complement Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Complement Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Complement Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Complement Inhibitors Market

17. China Complement Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Apellis Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol Myers Squibb Company
  • 18.13. Catalyst Biosciences, Inc.
  • 18.14. Eli Lilly and Company
  • 18.15. Horizon Therapeutics plc
  • 18.16. Ionis Pharmaceuticals, Inc.
  • 18.17. Janssen Pharmaceuticals, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi
  • 18.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPLEMENT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPLEMENT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RNAI THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RNAI THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RNAI THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GENERALIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GENERALIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GENERALIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEPHROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEPHROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEPHROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 209. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 211. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 212. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 245. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 248. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 257. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 259. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 260. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)